Menu Search
Equities

Intuitive Surgical Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IUI1:STU

Intuitive Surgical Inc

Actions
  • Price (EUR)458.35
  • Today's Change2.55 / 0.56%
  • Shares traded8.00
  • 1 Year change+10.63%
  • Beta1.6488
Data delayed at least 15 minutes, as of Jun 27 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.

  • Revenue in USD (TTM)8.71bn
  • Net income in USD2.48bn
  • Incorporated1995
  • Employees15.64k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ISRG:NSQ since
announced		Transaction
value
Ab Medica Spa-Da Vinci & Ion Distribution BusinessAnnounced21 Jan 202521 Jan 2025Announced-8.35%--
Data delayed at least 15 minutes, as of Jun 30 2025 20:30 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.